Twist Bioscience Corp senior vice president of human resources Paula Green reported an open-market sale of common stock. On February 17, 2026, she sold 39,404 shares at a weighted average price of $52.40 per share, and held 126,041 shares afterward.
Twist Bioscience Corp President and COO Patrick John Finn reported multiple transactions in the company’s stock. On February 17, 2026, he exercised two stock options covering 32,300 and 18,205 shares of common stock.
On the same date, he sold a total of 68,967 shares of common stock in open-market transactions at weighted average prices of $50.321, $51.423, $52.686 and $53.110 per share under a pre-established Rule 10b5-1 trading plan adopted on May 13, 2025. After these transactions, he directly owned 287,788 shares of Twist Bioscience common stock.
Twist Bioscience director Robert Chess reported a small tax-related share sale. On February 13, 2026, 2,184 shares of Twist Bioscience common stock were sold at $48.261 per share to cover tax liabilities arising from the vesting of restricted stock units, pursuant to a prior election rather than a discretionary trade. Following this transaction, Chess directly held 21,084 common shares. He also indirectly held 42,528 common shares through the Chess 1997 Trust, where he and his spouse serve as the sole trustees and beneficiaries.
Twist Bioscience insider Paula Green filed a Form 144 to sell up to 16,739 shares of common stock through Fidelity Brokerage Services LLC on or around 02/17/2026 on NASDAQ, with an aggregate market value of 877,123.60.
The notice shows these shares against a baseline of 61,311,704 common shares outstanding. The securities to be sold were mainly acquired through restricted stock vesting and one employee stock purchase plan transaction between 09/19/2024 and 02/20/2025, generally as compensation.
The filing also lists prior sales by Paula Green over the past three months, totaling 2,942 common shares on several dates, for combined gross proceeds of 109,727.69. By signing, the seller represents having no undisclosed material adverse information about Twist Bioscience’s operations.
A person associated with symbol TWST has filed a Form 144 notice to sell 22,665 shares of common stock. The planned sale, through Fidelity Brokerage Services LLC on NASDAQ, has an aggregate market value of $1,187,646.00 and an approximate sale date of 02/17/2026.
The filing lists 61,311,704 shares outstanding for this class of common stock; this is a baseline figure, not the amount being sold. The notice also discloses prior sales over the past three months by the same person, consistent with Rule 144 reporting requirements.
Twist Bioscience insider Patrick Finn filed a notice of proposed sale of 68,967 shares of the company’s common stock under Rule 144. The shares have an aggregate market value of $3,562,414.66 and are to be sold through Fidelity Brokerage Services LLC on NASDAQ.
The filing notes that 61,311,704 shares of common stock were outstanding, providing context for the planned sale. It also lists how Finn acquired these securities over time, including option grants and exercises, restricted stock vesting, and employee stock purchase plan participation, as well as his common stock sales in the prior three months.
Twist Bioscience Corp’s President and COO Patrick John Finn reported option exercises and share sales in a pre-planned trading program. On February 12 and 13, 2026, he exercised multiple stock options for common stock at exercise prices of $23.33 and $26.66 per share, converting them into ordinary shares. Over the same two days, he sold 3,500 and 1,750 shares of common stock in open-market transactions at weighted average prices of about $50.225 and $50.041 per share, with individual sale prices ranging from $50.00 to $50.51. All transactions were executed under a Rule 10b5-1 trading plan adopted on May 13, 2025, and he held 306,250 common shares directly after the reported trades, along with remaining vested stock options.
EdgePoint Investment Group Inc. reported a significant ownership position in Twist Bioscience Corp common stock. As of December 31, 2025, EdgePoint beneficially owned 5,377,991 shares, representing 8.80% of the outstanding common stock.
EdgePoint, an investment adviser based in Ontario, Canada, has sole voting and dispositive power over 4,165,651 shares and shared voting and dispositive power over 1,212,340 shares. The stake is held in the ordinary course of business and not for the purpose of changing or influencing control of Twist Bioscience.
Twist Bioscience Corporation has filed a prospectus supplement registering up to 632,328 shares of common stock for resale by existing selling securityholders. These shares are issuable under Stock Purchase Agreements dated February 11, 2026, and may be sold over time in various types of negotiated or market transactions.
The selling securityholders, including Invenra Inc. and other smaller holders, will receive all proceeds from any share sales, while Twist will receive no proceeds from these resales and will only cover registration-related expenses. The company’s common stock trades on the Nasdaq Global Select Market under the symbol TWST.
Twist Bioscience Corporation entered into stock purchase agreements with Invenra Inc. and two of Invenra’s investors. Twist will issue up to 632,328 shares of common stock. Up to 324,558 shares plus $5 million in cash will be provided to Invenra in exchange for a license agreement and certain technology. Twist will also issue up to 307,770 shares to two Invenra investors in exchange for preferred stock, giving Twist approximately a 6% ownership stake in Invenra. Twist gains the right to designate one director to Invenra’s board, whose members, including the Twist designee, may approve two additional directors. The company simultaneously granted registration rights and is filing a prospectus supplement to register the resale of these shares.